CC
ALXN

CQS Cayman’s Alexion Pharmaceuticals ALXN Stock Holding History

CQS Cayman’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15,000
Closed -$2.6M – 228
2015
Q1 		$2.6M Sell
15,000
-21,286
-59% -$3.85M 0.12% 115
2014
Q4 		$6.71M Buy
+36,286
New +$6.72M 0.45% 59

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CQS Cayman's ALXN Position: Q2 2015 in Review

CQS Cayman sold out of Alexion Pharmaceuticals (ALXN) in Q2 2015, closing a stake of 15,000 shares — an estimated $2.6M sold.

CQS Cayman first reported a position in ALXN in Q4 2014 and held it in 2 quarters. The position peaked at $6.71M in Q4 2014. 547 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

  • CQS Cayman reported no remaining Alexion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • CQS Cayman sold 15,000 Alexion Pharmaceuticals shares in Q2 2015, an estimated $2.6M.
  • CQS Cayman first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • CQS Cayman's Alexion Pharmaceuticals position peaked at $6.71M in Q4 2014.
  • 547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on CQS Cayman's 13F filing for Q2 2015, filed 12 Aug 2015.